The current review was used to find out the function of liquisolid technology to upgrade the rate of dissolution of mosapride citrate (BCS class II). Different Liquisolid formulations were prepared by utilizing polyethylene glycol 400 as a non-volatile fit, Avicel PH 102 as a carrier and Aerosil 200 as a covering material. Liquisolid tablets ware from FTIR, DSC, XRD and in-vitro dissolution studies. Characterisation studies registered that interactions were missing between drug and carrier, decline in the crystallinity and that will support further the augmentation of solubility and rate of dissolution. The optimised expression showed a important increase in dissolution that is, 99.69±1.47% in 30 min distinguished to directly compressible tablets (31.48±1.58%). DE (dissolution effectiveness) was increased from 15.16 % for direct condensation tablet to 70.5% for mosapride citrate liquisolid tablets. MDT (mean death time) of mosapride citrate was considerably reduced from 57.27 brief time period for direct compression tablet to 7.58 brief time period for optimized expression indicating faster release of drug. Liquisolid tablets maybe a promising form for of improvement of solubility, augmentation of dissolution and bioavailability of mosapride citrate.
Author(s) Details:
Bhaskar Daravath,
Department
of Pharmaceutics, GITAM School of Pharmacy, GITAM Deemed to be University,
Hyderabad, Telangana-502329, India.
Sateesh
Kumar Vemula,
Department
of Pharmaceutics, MAK College of Pharmacy, Moinabad, Ranga Reddy, Telangana
-501504, India.
Please see the link here: https://stm.bookpi.org/COPS-V2/article/view/9172
No comments:
Post a Comment